$142 Million is the total value of EMORY UNIVERSITY's 46 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 24.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BRKA | BERKSHIRE HATHAWAY INC DELcl a | $37,247,000 | +5.7% | 117 | 0.0% | 26.22% | +5.8% | |
| JD | JD COM INCspon adr cl a | $12,041,000 | +0.5% | 397,528 | 0.0% | 8.48% | +0.6% | |
| ARRY | New | ARRAY BIOPHARMA INC | $4,011,000 | – | 86,567 | +100.0% | 2.82% | – |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $3,213,000 | +46.3% | 131,041 | -43.2% | 2.26% | +46.6% |
| MRTX | New | MIRATI THERAPEUTICS INC | $3,160,000 | – | 30,680 | +100.0% | 2.22% | – |
| RARX | Sell | RA PHARMACEUTICALS INC | $2,944,000 | +10.5% | 97,916 | -17.7% | 2.07% | +10.6% |
| ZGNX | Buy | ZOGENIX INC | $2,862,000 | +2.5% | 59,905 | +18.0% | 2.01% | +2.7% |
| EIDX | New | EIDOS THERAPEUTICS INC | $2,606,000 | – | 83,836 | +100.0% | 1.83% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $2,599,000 | – | 27,551 | +100.0% | 1.83% | – |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $2,566,000 | – | 95,462 | +100.0% | 1.81% | – |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $2,564,000 | -8.6% | 132,255 | -2.1% | 1.80% | -8.4% |
| GHDX | Buy | GENOMIC HEALTH INC | $2,499,000 | +24.6% | 42,966 | +50.1% | 1.76% | +24.8% |
| RTRX | Buy | RETROPHIN INC | $2,483,000 | -0.8% | 123,600 | +11.7% | 1.75% | -0.6% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $2,465,000 | +0.0% | 94,475 | +48.9% | 1.74% | +0.2% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $2,450,000 | -1.7% | 29,020 | +2.6% | 1.72% | -1.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS | $2,447,000 | +13.4% | 645,583 | +143.6% | 1.72% | +13.6% |
| INCY | Buy | INCYTE CORP | $2,440,000 | -0.5% | 28,714 | +0.7% | 1.72% | -0.4% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $2,424,000 | +9.7% | 23,131 | +31.2% | 1.71% | +9.9% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $2,411,000 | -12.5% | 90,188 | -12.1% | 1.70% | -12.3% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $2,403,000 | -15.4% | 192,533 | -7.8% | 1.69% | -15.3% |
| HRTX | Buy | HERON THERAPEUTICS INC | $2,398,000 | +13.5% | 129,020 | +49.2% | 1.69% | +13.7% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $2,388,000 | -4.1% | 18,235 | -1.1% | 1.68% | -4.0% |
| SGEN | Buy | SEATTLE GENETICS INC | $2,325,000 | -4.9% | 33,593 | +0.7% | 1.64% | -4.7% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $2,251,000 | -0.1% | 26,278 | +3.6% | 1.58% | 0.0% |
| BGNE | Sell | BEIGENE LTDsponsored adr | $2,207,000 | -7.3% | 17,807 | -1.3% | 1.55% | -7.2% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $2,111,000 | -44.8% | 18,334 | -43.5% | 1.49% | -44.7% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $2,070,000 | -14.6% | 39,349 | -14.0% | 1.46% | -14.4% |
| THOR | Buy | SYNTHORX INC | $2,041,000 | -16.3% | 151,048 | +26.2% | 1.44% | -16.2% |
| C | Sell | CITIGROUP INC | $2,027,000 | +8.5% | 28,938 | -3.6% | 1.43% | +8.7% |
| CBRE | Buy | CBRE GROUP INCcl a | $2,003,000 | +5.0% | 39,052 | +1.3% | 1.41% | +5.2% |
| STX | Buy | SEAGATE TECHNOLOGY PLC | $1,992,000 | -1.5% | 42,275 | +0.1% | 1.40% | -1.3% |
| BHC | Buy | BAUSCH HEALTH COS INC | $1,970,000 | +5.2% | 78,121 | +3.0% | 1.39% | +5.4% |
| ACA | Sell | ARCOSA INC | $1,967,000 | +5.0% | 52,264 | -14.8% | 1.38% | +5.2% |
| KKR | Sell | KKR & CO INCcl a | $1,944,000 | +0.9% | 76,943 | -6.2% | 1.37% | +1.0% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $1,897,000 | -12.8% | 86,208 | +8.6% | 1.34% | -12.7% |
| MS | Sell | MORGAN STANLEY | $1,897,000 | -2.2% | 43,300 | -5.8% | 1.34% | -2.1% |
| TRN | Buy | TRINITY INDS INC | $1,880,000 | +14.2% | 90,599 | +19.6% | 1.32% | +14.3% |
| SLM | Buy | SLM CORP | $1,855,000 | +10.1% | 190,827 | +12.2% | 1.31% | +10.3% |
| ADS | Buy | ALLIANCE DATA SYSTEMS CORP | $1,826,000 | -6.4% | 13,028 | +16.9% | 1.28% | -6.3% |
| ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $1,726,000 | -38.3% | 123,400 | -21.1% | 1.22% | -38.2% |
| MYOV | Buy | MYOVANT SCIENCES LTD | $1,611,000 | -39.7% | 177,988 | +59.0% | 1.13% | -39.6% |
| SMLP | SUMMIT MIDSTREAM PARTNERS LP | $651,000 | -23.6% | 87,560 | 0.0% | 0.46% | -23.5% | |
| HD | New | HOME DEPOT INC | $378,000 | – | 1,819 | +100.0% | 0.27% | – |
| COCP | COCRYSTAL PHARMA INC | $359,000 | -13.9% | 152,916 | 0.0% | 0.25% | -13.7% | |
| SPY | SPDR S&P 500 ETF TRtr unit | $276,000 | +3.8% | 942 | 0.0% | 0.19% | +3.7% | |
| IFRX | Sell | INFLARX NV | $185,000 | -93.2% | 58,449 | -18.7% | 0.13% | -93.2% |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -47,779 | -100.0% | -1.51% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -97,035 | -100.0% | -1.55% | – |
| ATNX | Exit | ATHENEX INC | $0 | – | -188,696 | -100.0% | -1.62% | – |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -18,819 | -100.0% | -1.65% | – |
| SLDB | Exit | SOLID BIOSCIENCES INC | $0 | – | -298,887 | -100.0% | -1.93% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TR | 23 | Q3 2020 | 71.4% |
| SEATTLE GENETICS INC | 22 | Q2 2019 | 3.7% |
| MORGAN STANLEY | 22 | Q2 2019 | 1.7% |
| VANGUARD INTL EQUITY INDEX F | 18 | Q3 2015 | 100.0% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q2 2019 | 3.3% |
| MICROSOFT CORP | 17 | Q1 2018 | 1.9% |
| CITIGROUP INC | 16 | Q2 2019 | 1.4% |
| GENOMIC HEALTH INC | 15 | Q3 2019 | 3.6% |
| EXPRESS SCRIPTS HLDG CO | 15 | Q1 2018 | 3.8% |
| ACADIA PHARMACEUTICALS INC | 14 | Q2 2019 | 3.8% |
View EMORY UNIVERSITY's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| GeoVax Labs, Inc. | March 29, 2018 | 4,621,405 | 3.5% |
| Geovax Labs, Inc. | October 10, 2006 | 233,905,253 | 33.0% |
View EMORY UNIVERSITY's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-06 |
| 13F-HR | 2024-02-01 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-11 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-13 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-09 |
| 13F-HR | 2019-02-12 |
View EMORY UNIVERSITY's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.